What are the possible side effects of dabrafenib?

Dabrafenib is a BRAF inhibitor that mainly targets the BRAF V600E mutation and is used to treat advanced melanoma, thyroid cancer, non-small cell lung cancer, etc. During treatment with dabrafenib, patients may experience a series of side effects, which are usually related to the drug's interference with cancer cell signaling pathways and affecting the physiological regulatory mechanisms of normal tissues.

One of the most common side effects is fever. Some patients will experience periodic increases in body temperature in the early stages of treatment, especially when combined with trametinib (Trametinib). Some patients will experience general discomfort such as chills, fatigue, and muscle aches, suggesting the need to be wary of drug-related inflammatory reactions. In addition, skin adverse reactions are also relatively common, such as rash, photosensitivity, hand-foot syndrome, etc. Some patients may also experience skin itching, desquamation, etc.

In terms of the digestive system, patients may experience nausea, loss of appetite, dry mouth, or mild diarrhea, which can usually be relieved through dietary modification and auxiliary medications. In terms of liver and kidney function, long-term medication requires close monitoring of changes in liver enzymes and indicators such as creatinine and urea to prevent aggravation of adverse reactions. In addition, some individuals may be at risk for joint pain, blurred vision, and even rare electrical conduction abnormalities in the heart.

Overall, dabrafenib, as a targeted drug, has certain regularity and controllability in its side effects. Most side effects can be gradually relieved after drug dosage reduction or symptomatic treatment, and will not affect the overall treatment process. Patients should insist on regular review while taking the medication and follow the monitoring and intervention plan formulated by the doctor. Only in this way can the effects of toxic and side effects be minimized while ensuring the efficacy, thereby achieving long-term disease control.

Reference materials:https://go.drugbank.com/drugs/DB08912